NCT03380468View on ClinicalTrials.gov

Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 1, 2024

Study Completion Date

December 31, 2025

Conditions

Lung Neoplasms

Interventions

DRUG

cisplatin plus pemetrexed

cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv

Trial Locations (1)

200032

RECRUITING

Fudan University Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER